UroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024

RTTNews | 758 ngày trước
UroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024

(RTTNews) - Biotech company UroGen Pharma Ltd. (URGN) announced Tuesday that it has reached agreement with the U.S. Food and Drug Administration (FDA) on plans for submission of a New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution.

The FDA indicated that the current clinical development plan for UGN-102, which includes evaluation of duration of complete response (CR) at 12 months from the pivotal ENVISION trial, will support submission of an NDA for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the Chemistry, Manufacturing and Controls (CMC) sections of the NDA, which is planned for January 2024.

If approved, UGN-102 has the potential to introduce a new non-surgical treatment paradigm for LG-IR-NMIBC, a subset of bladder cancer patients characterized by high recurrence rates and the need for multiple surgeries.

The UGN-102 clinical development plan centers around the Phase 3 ENVISION pivotal trial and is supported by robust clinical data from the ATLAS Phase 3 and OPTIMA Phase 2b trials.

read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | 575 ngày trước
Sensex, Nifty Modestly Higher In Early Trade

Sensex, Nifty Modestly Higher In Early Trade

Indian shares were slightly higher on Friday despite mixed cues from global markets. The benchmark BSE Sensex was up 180 points, or 0.2 percent, at 84,583 in early trade, while the broader NSE Nifty index edged up by 38 points, or 0.2 percent, to 25,915.
RTTNews | 15 phút trước
Australian Market Trims Early Gains In Mid-market

Australian Market Trims Early Gains In Mid-market

The Australian stock market is trimming its early gains in mid-market moves on Friday, snapping a three-session losing streak, despite the broadly negative cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving above the 8,900 level, with strong gains in gold miner stocks partially offset by weakness in technology stocks.
RTTNews | 1h 14phút trước
Asian Markets Trade Mixed

Asian Markets Trade Mixed

Asian markets are trading mixed on Friday, following the negative cues from Wall Street overnight, amid renewed uncertainty about the outlook for interest rates after Fed Chair Jerome Powell said a further reduction in rates in December is "not a foregone conclusion. Positive developments out of US President Donald Trump's meeting with Chinese President Xi Jinping is aiding market sentiment.
RTTNews | 1h 20phút trước
Japanese Market Sharply Higher

Japanese Market Sharply Higher

Extending the gains in the previous two sessions, the Japanese market is sharply higher on Friday, despite the broadly negative cues from Wall Street overnight. The Nikkei 225 is moving above the 52,200 level to fresh all-time highs, with gains in index heavyweights, exporters and technology stocks partially offset by weakness in automakers and financial stocks.
RTTNews | 3h 6phút trước
Australian Market Notably Higher

Australian Market Notably Higher

The Australian stock market is trading notably higher on Friday, snapping a three-session losing streak, despite the broadly negative cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving above the 8,900 level, with gains in gold miners and financial stocks.
RTTNews | 3h 40phút trước